Cholyl-iFluor™647缀合物

产品基本信息

产品名称：Cholyl-iFluor™647缀合物

储存条件：-15℃避光防潮

保质期：12个月

 

产品物理化学光谱特性

分子量：1289.57

外观：固体

溶剂：DMSO

Ex(nm):656

Em(nm):670

 

产品介绍

Cholyl-iFluor™647缀合物是我们绿色荧光Cholyl-Lys-Fluorescein（＃36701）的红色荧光类似物。它是iFluor™647标记的胆汁酸衍生物，与胆酸衍生物的细胞结合和摄取特性极为相似。它是一种二价的“单极性”阴离子荧光一羟基胆汁盐类似物，其物理，生物学和胆汁抑制特性与石胆酸盐，乙醇胆酸及其衍生物相似，因此是研究单羟基胆汁盐引起的胆汁淤积的机制的优质探针。

点击查看光谱

 

参考文献

Novel hypolipidemic conjugates of fatty acid and bile acid with lysine for linkage.
Authors: Jin, Xue-Yuan and Zhu, Chuan-Bao and Fan, Shi-Yong and Sun, Jia-Lin and Shi, Yu-Cong and Wang, Chu-Han and Wang, Hui-Fen and Zhong, Bo-Hua and Yao, Yi-Shan and Shi, Wei-Guo
Journal: Drug development and industrial pharmacy (2019): 995-998

L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease.
Authors: Voloshin, Irina and Hahn-Obercyger, Michal and Anavi, Sarit and Tirosh, Oren
Journal: Lipids in health and disease (2014): 69

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
Authors: Safadi, Rifaat and Konikoff, Fred M and Mahamid, Mahmud and Zelber-Sagi, Shira and Halpern, Maya and Gilat, Tuvia and Oren, Ran
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2014): 2085-91.e1

Amino acid-bile acid based molecules: extremely narrow surfactant nanotubes formed by a phenylalanine-substituted cholic acid.
Authors: Travaglini, Leana and D'Annibale, Andrea and Schillén, Karin and Olsson, Ulf and Sennato, Simona and Pavel, Nicolae V and Galantini, Luciano
Journal: Chemical communications (Cambridge, England) (2012): 12011-3

Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic.
Authors: Leikin-Frenkel, Alicia and Gonen, Ayelet and Shaish, Aviv and Goldiner, Ilana and Leikin-Gobbi, Diana and Konikoff, Fred M and Harats, Dror and Gilat, Tuvia
Journal: Archives of medical research (2010): 397-404

Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice.
Authors: Leikin-Frenkel, Alicia and Parini, Paolo and Konikoff, Fred M and Benthin, Lisbet and Leikin-Gobbi, Diana and Goldiner, Ilana and Einarsson, Curt and Gilat, Tuvia
Journal: Archives of biochemistry and biophysics (2008): 63-71

Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents.
Authors: Leikin-Frenkel, Alicia and Goldiner, Ilana and Leikin-Gobbi, Diana and Rosenberg, Ruth and Bonen, Hamutal and Litvak, Alex and Bernheim, Joelle and Konikoff, Fred M and Gilat, Tuvia
Journal: European journal of gastroenterology & hepatology (2008): 1205-13

[Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)].
Authors: Keizman, Daniel and Goldiner, Ilana and Leikin-Frenkel, Alicia and Konikoff, Fred M
Journal: Harefuah (2008): 344-9, 373, 372

ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs).
Authors: Goldiner, Ilana and van der Velde, Astrid E and Vandenberghe, Kristin E and van Wijland, Michel A and Halpern, Zamir and Gilat, Tuvia and Konikoff, Fred M and Veldman, Robert Jan and Groen, Albert K
Journal: The Biochemical journal (2006): 529-36

New targets in and potential treatments for cholesterol gallstone disease.
Authors: Doggrell, Sheila A
Journal: Current opinion in investigational drugs (London, England : 2000) (2006): 344-8